Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006246 · ClinicalTrials.gov registry record · Phase 1

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

A Phase 1 study of Lymphoma and Leukemia, sponsored by Pediatric Brain Tumor Consortium.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
8
Study locations

NCT00006246 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 28 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006246, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Pediatric Brain Tumor Consortium.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
8
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose of this treatment regimen.

Conditions Studied

Lymphoma Leukemia Sarcoma Metastatic Cancer Brain and Central Nervous System Tumors Retinoblastoma Childhood Germ Cell Tumor

Interventions

  • DRUG busulfan

Study Locations (8)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Children's Hospital of Pittsburgh - Pittsburgh

California

  • UCSF Cancer Center and Cancer Research Institute - San Francisco

District of Columbia

  • Children's National Medical Center - Washington D.C.

Massachusetts

  • Dana-Farber Cancer Institute - Boston

North Carolina

  • Duke Comprehensive Cancer Center - Durham

Texas

  • Baylor College of Medicine - Houston

Washington

  • Children's Hospital and Regional Medical Center - Seattle - Seattle

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2000-11
Phase Phase 1

Sponsor

Pediatric Brain Tumor Consortium

27 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006246

The ClinicalTrials.gov registry entry for NCT00006246 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which busulfan is the first listed.

NCT00006246 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00006246 about?

NCT00006246 is a clinical study titled "Busulfan in Treating Children and Adolescents With Refractory CNS Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose...

What is the current status of trial NCT00006246?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2000-11.

What conditions does trial NCT00006246 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia, Sarcoma, Metastatic Cancer, Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00006246?

The interventions under investigation include: busulfan (DRUG).

Who is sponsoring clinical trial NCT00006246?

This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006246 being conducted?

This trial has 8 study locations across California, District of Columbia, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.